The varicella vaccine. Clinical trials in immunocompromised individuals.
A review of the use of live attenuated varicella vaccine in immunocompromised children, particularly those with underlying leukemia in remission, is presented. Data concerning safety, immunogenicity, and efficacy of this vaccine in high-risk children are reviewed. The unique contributions toward our understanding of varicella vaccine, including spread of vaccine-type virus, incidence of zoster, and immune correlates provided by studies of immunocompromised patients are discussed. The importance of protecting high-risk children against severe varicella by the use of varicella vaccine is apparent.
Gershon
A A
AA
Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA.
LaRussa
P
P
Steinberg
S
S
D002170:Canada; D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006562:Herpes Zoster / Q000517:prevention & control; D006801:Humans; D016867:Immunocompromised Host; D007564:Japan; D014481:United States
D019433:Chickenpox Vaccine